Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 6/20 | 0.61 |
| ▸ | MAOB | P27338 | 3/20 | 0.61 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.57 |
| ▸ | SDHA | P31040 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | CALML3 | P27482 | 1/20 | 0.57 |
| ▸ | F10 | P00742 | 4/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6161177 | 1.00 | MAOA (0.61) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL6160326 | 1.00 | MAOA (0.61) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL6162524 | 1.00 | MAOA (0.61) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL6160328 | 1.00 | MAOA (0.61) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL7846895 | 0.92 | MAOA (0.54) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL7832146 | 0.92 | MAOA (0.54) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL6160348 | 0.92 | MAOA (0.54) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL6164089 | 0.92 | MAOA (0.54) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL8108944 | 0.91 | MAOA (0.51) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL8117477 | 0.90 | MAOB (0.59) | MAOAMAOBPTGS1SDHALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1083900-A2 | TOPICAL ADMINISTRATION OF OXAZOLIDINONES FOR TRANSDERMAL DELIVERY | PHARMACIA & UPJOHN COMPANY (US) | 2001-03-21 | — | — | EP | claimed |
| EP-1036074-A1 | S-OXIDE AND S,S-DIOXIDE TETRAHYDROTHIOPYRAN PHENYLOXAZOLIDINONES | PHARMACIA & UPJOHN COMPANY (US) | 2000-09-20 | — | — | EP | claimed |
| EP-1032386-A1 | USE OF OXAZOLIDINONE DERIVATITIVES FOR TREATING PSORIASIS, ARTHRITIS AND REDUCING THE TOXICITY OF CANCER CHEMOTHERAPY | PHARMACIA & UPJOHN COMPANY (US) | 2000-09-06 | — | — | EP | claimed |
| WO-1999062504-A2 | TOPICAL ADMINISTRATION OF OXAZOLIDINONES FOR TRANSDERMAL DELIVERY | PHARMACIA & UPJOHN COMPANY (US) | 1999-12-09 | — | — | WO | claimed |
| WO-1999029688-A1 | S-OXIDE AND S,S-DIOXIDE TETRAHYDROTHIOPYRAN PHENYLOXAZOLIDINONES | PHARMACIA & UPJOHN COMPANY (US) | 1999-06-17 | — | — | WO | claimed |
| WO-1999025344-A1 | USE OF OXAZOLIDINONE DERIVATIVES FOR TREATING PSORIASIS, ARTHRITIS AND REDUCING THE TOXICITY OF CANCER CHEMOTHERAPY | PHARMACIA & UPJOHN COMPANY (US) | 1999-05-27 | — | — | WO | claimed |
| WO-2003030906-A1 | TREATING INFECTIONS BY ADMINISTRATION OF OXAZOLIDINONES TO THE SKIN | PHARMACIA & UPJOHN COMPANY (US) | 2003-04-17 | — | — | WO | disclosed |
| EP-1083900-A2 | TOPICAL ADMINISTRATION OF OXAZOLIDINONES FOR TRANSDERMAL DELIVERY | PHARMACIA & UPJOHN COMPANY (US) | 2001-03-21 | — | — | EP | disclosed |
| EP-1036074-A1 | S-OXIDE AND S,S-DIOXIDE TETRAHYDROTHIOPYRAN PHENYLOXAZOLIDINONES | PHARMACIA & UPJOHN COMPANY (US) | 2000-09-20 | — | — | EP | disclosed |
| WO-1999062504-A2 | TOPICAL ADMINISTRATION OF OXAZOLIDINONES FOR TRANSDERMAL DELIVERY | PHARMACIA & UPJOHN COMPANY (US) | 1999-12-09 | — | — | WO | disclosed |
| WO-1999029688-A1 | S-OXIDE AND S,S-DIOXIDE TETRAHYDROTHIOPYRAN PHENYLOXAZOLIDINONES | PHARMACIA & UPJOHN COMPANY (US) | 1999-06-17 | — | — | WO | disclosed |